Diagnosis and management of hypersensitivity reactions related to common cancer chemotherapy agents

Annals of Allergy, Asthma and Immunology

Volumn 102, Issue 3, 2009, Pages 179-187

  Lee, Christina ^a   Gianos, Mary ^a   Klaustermeyer, William B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; ANTINEOPLASTIC AGENT; ASPARAGINASE; ASPARAGINASE MACROGOL; CARBAMAZEPINE; CARBOPLATIN; CIMETIDINE; CISPLATIN; CORTICOSTEROID; CREMOPHOR; CYCLOSPORIN; DEXAMETHASONE; DIPHENHYDRAMINE; DOCETAXEL; ETOPOSIDE; FLUOROURACIL; IMMUNOGLOBULIN E; OXALIPLATIN; PACLITAXEL; PHENOBARBITAL; PHENYTOIN; POLYSORBATE 80; PREDNISONE; PROCARBAZINE; RANITIDINE; TENIPOSIDE; VINCRISTINE; VITAMIN K GROUP;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ALLERGIC PNEUMONITIS; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ASCITES; BRONCHOSPASM; CAPILLARY LEAK SYNDROME; CHEST TIGHTNESS; CLINICAL PROTOCOL; COMPLEMENT ACTIVATION; COUGHING; DEATH; DESENSITIZATION; DIARRHEA; DISEASE ASSOCIATION; DOSAGE SCHEDULE COMPARISON; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; FEVER; HEMOLYTIC ANEMIA; HUMAN; HYPERSENSITIVITY REACTION; HYPOTENSION; HYPOXIA; INTRACUTANEOUS TEST; LUNG TOXICITY; MACULOPAPULAR RASH; MULTIPLE CYCLE TREATMENT; PERIPHERAL EDEMA; PLEURA EFFUSION; PREMEDICATION; PRIORITY JOURNAL; RASH; REVIEW; RIGOR; SIDE EFFECT; SKIN MANIFESTATION; STRIDOR; TOXIC EPIDERMAL NECROLYSIS; TREATMENT INDICATION; URTICARIA;

EID: 63449112670     PISSN: 10811206     EISSN: 15344436     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)60078-6     Document Type: Review

References (80)

1. Shepherd GM. Hypersensitivity reactions to chemotherapeutic drugs. Clin Rev Allergy Immunol. 2003;24:253-262.
2. Cleare MK, Hughes EG, Jacoby B, Pepys J. Immediate (type I) allergic responses to platinum compounds. Clin Allergy. 1976;6:183-195.
3. Markman M, Kennedy A, Webster K, et al. Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol. 1999;17:1141-1145.
4. Sliesoraitis S, Chikhale PJ. Carboplatin hypersensitivity. Int J Gynecol Cancer. 2005;15:13-18.
5. Weiss RB. Hypersensitivity reactions. Semin Oncol. 1992;19:458-477.
6. Kook H, Kim KM, Choi SH, et al. Life-threatening carboplatin hypersensitivity during conditioning for autologous PBSC transplantation: successful rechallenge after desensitization. Bone Marrow Transplant. 1998;21:727-729.
7. Zweizig S, Roman LD, Muderspach LI. Death from anaphylaxis to cisplatin: a case report. Gynecol Oncol. 1994;53:121-122.
8. Zanotti KM, Rybicki LA, Kennedy AW, et al. Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy. J Clin Oncol. 2001;19:3126-3129.
9. Markman M, Zanotti K, Peterson G, Kulp B, Webster K, Belinson J. Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity. J Clin Oncol. 2003; 21:4611-4614.
10. Dizon DS, Sabbatini PJ, Aghajanian C, Hensley ML, Spriggs DR. Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy. Gynecol Oncol. 2002;84:378 -382.
11. Rose PG, Fusco N, Smrekar M, Mossbruger K, Rodriguez M. Successful administration of carboplatin in patients with clinically documented carboplatin hypersensitivity. Gynecol Oncol. 2003;89:429-433.
12. Choi J, Harnett P, Fulcher DA. Carboplatin desensitization. Ann Allergy Asthma Immunol. 2004;93:137-141.
13. Markman M, Hsieh F, Zanotti K, et al. Initial experience with a novel desensitization strategy for carboplatin-associated hypersensitivity reactions: carboplatin-hypersensitivity reactions. J Cancer Res Clin Oncol. 2004;130:25-28.
14. Confino-Cohen R, Fishman A, Altaras M, Goldberg A. Successful carboplatin desensitization in patients with proven carboplatin allergy. Cancer. 2005;104:640-643.
15. Castells MC, Tennant NM, Sloane DE, et al. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitizations in 413 cases. J Allergy Clin Immunol. 2008;122:574-580.
16. Ottaiano A, Tambaro R, Greggi S, et al. Safety of cisplatin after severe hypersensitivity reactions to carboplatin in patients with recurrent ovarian carcinoma. Anticancer Res. 2003;23:3465-3468.
17. Jones R, Ryan M, Friedlander M. Carboplatin hypersensitivity reactions: re-treatment with cisplatin desensitization. Gynecol Oncol. 2003;89: 112-115.
18. Gowda A, Goel R, Berdzik J, Leichman CG, Javle M. Hypersensitivity reactions to oxaliplatin: incidence and management. Oncology. 2004;18: 1671-1674.
19. Oxaliplatin [package insert].
20. Brandi G, Pantaleo MA, Galli C, et al. Hypersensitivity reactions related to oxaliplatin (OHP). Br J Cancer. 2003;89:477-481.
21. Maindrault-Goebel F, Tournigand C, et al. Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patients. Eur J Cancer. 2005; 41:2262-2267.
22. Tournigand C, Maindrault-Goebel F, Louvet C, de Gramont A, Krulik M. Severe anaphylactic reactions to oxaliplatin. Eur J Cancer. 1998;34: 1298-1299.
23. Medioni J, Coulon MA, Morere JF, Hennebelle F, Piperno-Neumann S, Breau JL. Anaphylaxis after oxaliplatin. Ann Oncol. 1999;10:610.
24. Herrero T, Tornero P, Infante S, et al. Diagnosis and management of hypersensitivity reactions caused by oxaliplatin. J Investig Allergol Clin Immunol. 2006;16:327-330.
25. Thomas RR, Quinn MG, Schuler B, Grem JL. Hypersensitivity and idiosyncratic reactions to oxaliplatin. Cancer. 2003;97:2301-2307.
26. Bhargava P, Gammon D. Hypersensitivity and idiosyncratic reactions to oxaliplatin. Cancer. 2004;100:211-212.
27. Garufi C, Cristaudo A, Vanni B, et al. Skin testing and hypersensitivity reactions to oxaliplatin. Ann Oncol. 2003;14:497-502.
28. Meyer L, Zuberbier T, Worm M, Oettle H, Riess H. Hypersensitivity reactions to oxaliplatin: cross-reactivity to carboplatin and the introduction of a desensitization schedule. J Clin Oncol. 2002;20:1146-1147.
29. Pagani M, Bonadonna P, Senna GE, Antico A. Standardization of skin tests for diagnosis and prevention of hypersensitivity reactions to oxaliplatin. Int Arch Allergy Immunol. 2008;145:54-57.
30. Mis L, Fernando NH, Hurwitz HI, Morse MA. Successful desensitization to oxaliplatin. Ann Pharmacother. 2005;39:966-969.
31. Gammon D, Bhargava P, McCormick MJ. Hypersensitivity reactions to oxaliplatin and the application of a desensitization protocol. Oncologist. 2004;9:546-549.
32. Garufi C, Vaglio S, Brienza S, et al. Immunohemolytic anemia following oxaliplatin administration. Ann Oncol. 2000;11:497.
33. de Vries RS, Mattijssen EJ, van Sorge AA. Serious delayed hypersensitivity reaction to oxaliplatin. Ann Oncol. 2004;17:1723-1724.
34. Santini D, Tonini G, Salerno A, et al. Idiosyncratic reaction after oxaliplatin infusion. Ann Oncol. 2001;12:132-133.
35. Tonini G, Santini D, Vincenzi B, et al. Oxaliplatin may induce cytokine- release syndrome in colorectal cancer patients. J Biol Regul Homeost Agents. 2002;16:105-109.
36. Rowinsky EK, Donehower RC. Paclitaxel (Taxol). N Engl J Med. 1995;332:1004-1014.
37. Taxol (paclitaxel) injection [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; March 2003.
38. Weiss RB, Donehower RC, Wiernik PH, et al. Hypersensitivity reactions from taxol. J Clin Oncol. 1990;8:1263-1268.
39. Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nano-particle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005; 23:7794.
40. Bookman MA, Kloth DD, Kover PE, Smolinski S, Ozols RF. Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions. Ann Oncol. 1997;8:611-614.
41. Markman M, Kennedy A, Webster K, Peterson G, Kulp B, Belinson J. An effective and more convenient drug regimen for prophylaxis against paclitaxel-associated hypersensitivity reactions. J Cancer Res Clin Oncol. 1999;125:427-429.
42. Kwon JS, Elit L, Finn M, et al. A comparison of two prophylactic regimens for hypersensitivity reactions to paclitaxel. Gynecol Oncol. 2002;84:420-425.
43. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol. 1994;12:2654 -2666.
44. Olson JK, Sood AK, Sorosky JI, Anderson B, Buller RE. Taxol hypersensitivity: rapid retreatment is safe and cost effective. Gynecol Oncol. 1998;68:25-28.
45. Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J. Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center. J Clin Oncol. 2000;18:102-105.
46. Markman M. Managing taxane toxicities. Support Care Cancer. 2003; 11:144 -147.
47. Feldweg AM, Lee CW, Matulonis UA, Castells M. Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments. Gynecol Oncol. 2005;96:824-829.
48. Lokich J, Anderson N. Paclitaxel hypersensitivity reactions: a role for docetaxel substitution. Ann Oncol. 1998;9:573-574.
49. Moon C, Verschraegen CF, Bevers M, Freedman R, Kudelka AP, Kavanagh JJ. Use of docetaxel (Taxotere) in patients with paclitaxel (Taxol) hypersensitivity. Anticancer Drugs. 2000;11:565-568.
50. Dizon DS, Schwartz J, Rojan A, et al. Cross-sensitivity between paclitaxel and docetaxel in a women's cancers program. Gynecol Oncol. 2006;100:149-151.
51. Schrijvers D, Wanders J, Dirix L, et al. Coping with toxicities of docetaxel (Taxotere). Ann Oncol. 1993;4:610-611.
52. Ardavanis A, Tryfonopoulos D, Yiotis I, Gerasimidis G, Baziotis N, Rigatos G. Non-allergic nature of docetaxel-induced acute hypersensitivity reactions. Anticancer Drugs. 2004;15:581-585.
53. Semb KA, Aamdal S, Oian P. Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment. J Clin Oncol. 1998;16:3426-3432.
54. Piccart MJ, Klijn J, Paridaens R, et al. Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer. J Clin Oncol. 1997;15:3149-3155.
55. Asselin BL. The three asparaginases: comparative pharmacology and optimal use in childhood leukemia. Adv Exp Med Biol. 1999;457: 621-629.
56. Dellinger CT, Miale TD. Comparison of anaphylactic reactions to asparaginase derived from Escherichia Coli and from Erwinia cultures. Cancer. 1976;38:1843-1846.
57. Evans WE, Tsiatis A, Rivera G, et al. Anaphylactoid reactions to Escherichia coli and Erwinia asparaginase in children with leukemia and lymphoma. Cancer. 1982;49:1378-1383.
58. Weiss RB, Bruno S. Hypersensitivity reactions to cancer chemotherapeutic agents. Ann Intern Med. 1981;94:66-72.
59. Khan A, Hill JM. Atopic hypersensitivity to L-asparaginase: resistance to immunosuppression. Int Arch Allergy Appl Immunol. 1971;40:463-469.
60. Fabry U, Korholz D, Jurgens H, Gobel U, Wahn V. Anaphylaxis to L-asparaginase during treatment for acute lymphoblastic leukemia in children-evidence of a complement-medicated mechanism. Pediatr Res. 1985;19:400 -408.
61. Albo V, Miller D, Leiken S, et al. Toxicity experience with a second course of E. coli L-asparaginase (L-asp) therapy 3 years after induction course in children with acute lymphoblastic leukemia (ALL) in continuous remission. Proc Am Soc Clin Oncol. 1983;2:abstract.
62. Muller H, Beier R, Löning L, et al. Pharmacokinetics of native Escherichia coli asparaginase (Asparaginase medac) and hypersensitivity reactions in ALL-BFM 95 reinduction treatment. Br J Haematol. 2001; 114:794 -799.
63. Beard MEJ, Crowther D, Galton DA, et al. L-asparaginase in treatment of acute leukaemia and lymphosarcoma. BMJ. 1970;1:191-195.
64. Larson RA, Fretzin MH, Dodge RK, Schiffer CA. Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia. Leukemia. 1998;12:660-665.
65. Clavell LA, Gelber RD, Cohen HJ, et al. Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. N Engl J Med. 1986;315:657-663.
66. Holle LM. Pegasparagase: an alternative. Ann Pharmacother. 1997;31: 616-624.
67. Coyle T, Bushunow P, Winfield J, Wright J, Graziano S. Hypersensitivity reactions to procarbazine with mechlorethamine, vincristine, and procarbazine chemotherapy in the treatment of glioma. Cancer. 1992; 69:2532-2540.
68. Lehmann DF, Hurteau TE, Newman N, Coyle TE. Anticonvulsant usage is associated with an increased risk of procarbazine hypersensitivity reactions in patients with brain tumors. Clin Pharmacol Ther. 1997;62: 225-229.
69. Brooks BJ, Hendler NB, Alvarez S, Ancalmo N, Grinton SF. Delayed life-threatening pneumonitis secondary to procarbazine. Am J Clin Oncol. 1990;13:244-246.
70. Mahmood T, Mudad Raja. Pulmonary toxicity secondary to procarbazine. Am J Clin Oncol. 2002;25:187-188.
71. O'Dwyer PJ, King SA, Fortner CL, Leyland-Jones B. Hypersensitivity reactions to teniposide (VM-26): an analysis. J Clin Oncol. 1986;4: 1262-1269.
72. Kellie SJ, Crist WM, Pui CH, et al. Hypersensitivity reactions to epipodophyllotoxins in children with acute lymphoblastic leukemia. Cancer. 1991;67:1070-1075.
73. Zanotti KM, Markman M. Prevention and management of antineoplastic- induced hypersensitivity reactions. Drug Safety. 2001;24:767-779.
74. Hoetelmans RMW, Schornagel JH, Bokkeel Huinink WW, Beijnen JH. Hypersensitivity reactions to etoposide. Ann Pharmacother. 1996;30: 367-371.
75. Hartmann JT, Lipp HP. Camptothecin and podophyllotoxin derivatives. Drug Safety. 2006;29:209-230.
76. Nolte H, Carstensen H, Hertz H. VM-26 (teniposide)-induced hypersensitivity and degranulation of basophils in children. Am J Pediatr Hematol Oncol. 1988;10:308.
77. Carstensen H, Nolte H, Hertz H, Jensen T. Hypersensitivity reactions to
78. teniposide in children. J Clin Oncol. 1987;5:1491-1492.
79. Hudson MM, Weinstein HJ, Donaldson SS, et al. Acute hypersensitivity reactions to etoposide in a VEPA regimen for Hodgkin's disease. J Clin Oncol. 1993;11:1080-1084.
80. Siderov J, Prasad P, De Boer R, Desai J. Safe administration of etoposide phosphate after hypersensitivity reaction to intravenous etoposide. Br J Cancer. 2002;86:12-13.